These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 32787587)

  • 21. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
    Aristin Revilla S; Kranenburg O; Coffer PJ
    Front Immunol; 2022; 13():903564. PubMed ID: 35874729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on colorectal cancer microenvironment, epigenetic and immunotherapy.
    Jin K; Ren C; Liu Y; Lan H; Wang Z
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107041. PubMed ID: 33045561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell-based immunotherapy in colorectal cancer.
    Feng M; Zhao Z; Yang M; Ji J; Zhu D
    Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy and immunoevasion of colorectal cancer.
    Al Zein M; Boukhdoud M; Shammaa H; Mouslem H; El Ayoubi LM; Iratni R; Issa K; Khachab M; Assi HI; Sahebkar A; Eid AH
    Drug Discov Today; 2023 Sep; 28(9):103669. PubMed ID: 37328052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement System: An Immunotherapy Target in Colorectal Cancer.
    Talaat IM; Elemam NM; Saber-Ayad M
    Front Immunol; 2022; 13():810993. PubMed ID: 35173724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress.
    Rastin F; Javid H; Oryani MA; Rezagholinejad N; Afshari AR; Karimi-Shahri M
    Int Immunopharmacol; 2024 Jan; 126():111055. PubMed ID: 37992445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
    Kishore C; Bhadra P
    Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel avenues in immunotherapies for colorectal cancer.
    Pardieck IN; Jawahier PA; Swets M; van de Velde CJ; Kuppen PJ
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):465-80. PubMed ID: 26582071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential role of immunotherapy to treat colorectal cancer.
    Amin M; Lockhart AC
    Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer.
    Dmello RS; To SQ; Chand AL
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant Immunotherapy in Microsatellite-Instability High Nonmetastatic Colorectal Cancer: A Single-institute Experience and Review of the Literature.
    Kinney RE; Khalil M
    Clin Colorectal Cancer; 2021 Jun; 20(2):e109-e112. PubMed ID: 33722513
    [No Abstract]   [Full Text] [Related]  

  • 34. The colorectal cancer immune microenvironment and approach to immunotherapies.
    Koi M; Carethers JM
    Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
    [No Abstract]   [Full Text] [Related]  

  • 35. The evolving role of immune oncology in colorectal cancer.
    Dawood S
    Chin Clin Oncol; 2018 Apr; 7(2):17. PubMed ID: 29764162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy.
    Alzamami A
    Med Oncol; 2023 Nov; 40(12):352. PubMed ID: 37950801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing immunotherapy for colorectal cancer.
    Ganesh K
    Nat Rev Gastroenterol Hepatol; 2022 Feb; 19(2):93-94. PubMed ID: 34907331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for colorectal cancer.
    Koido S; Ohkusa T; Homma S; Namiki Y; Takakura K; Saito K; Ito Z; Kobayashi H; Kajihara M; Uchiyama K; Arihiro S; Arakawa H; Okamoto M; Gong J; Tajiri H
    World J Gastroenterol; 2013 Dec; 19(46):8531-42. PubMed ID: 24379570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
    Li X; Nie J; Mei Q; Han WD
    World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.